
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with ...
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) Results obtained using highest sensitivity test available; …